$LMRI

Analysts initiated coverage on five companies: Vertiv (VRT) with a $329 target, Vylor (VYLR) with an $84 target, Aether (ATHR) with a $10 target, Lumexa (LMRI) with an $18 target, and nVent (NVT) with a $212 target. All received positive ratings. Stock prices at close were $252.18, $67.26, $3.45, $10.32, and $169.56 respectively.

Analysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…

Lumexa (LMRI) was upgraded to a Zacks Rank #2 (Buy) due to upward earnings estimate revisions. The company is expected to earn $0.77 per share for the fiscal year ending December 2026, with a 1.3% increase in the Zacks Consensus Estimate over the past three months. This upgrade reflects positivity about its earnings outlook and potential for stock price increase.

Lumexa Imaging (LMRI) reported Q2 2026 revenue of $264.2M, up 5.1% YoY, with adjusted EBITDA of $56.4M. Net income turned positive at $2.7M, reversing a prior-year loss. Advanced imaging volume grew 6.8%, driving revenue increases. The company narrowed EBITDA guidance to $235M-$241M and highlighted expansion plans, including new PET machines and FastScan technology.

Lumexa Imaging Holdings, Inc. (LMRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lumexa Imaging Announces Second Quarter 2026 Results RALEIGH, N. C., August 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated it

Lumexa Imaging Holdings, Inc. (LMRI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d155301dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 7 AMENDMENT NO. 7, dated as of June 30, 2026 (this “ Amendment ”), by and among LUMEXA IMAGING, INC., a Delaware corporation (the “ LII Borrower ”), LUMEXA IMAGING OUTPATIENT, INC., a Delawar

Lumexa Imaging Holdings, Inc. (LMRI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002071288 0002071288 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10,

Lumexa Imaging (NASDAQ: LMRI) said it formed a strategic joint venture with Hospital for Special Surgery (HSS) to expand advanced outpatient imaging across the New York City metro area. The deal is Lumexa’s ninth joint venture and supports its growth strategy via de novo development, acquisitions, and partnerships. Lumexa reported about 4 million outpatient procedures system-wide in 2025.

Lumexa Imaging Holdings reported a 3% Q1 revenue increase to $253 million, with advanced modalities like PET and MRI showing strong growth. The company completed two acquisitions and two de novo openings, planning 8 to 10 more to drive future expansion, especially through strategic joint ventures. Adjusted EBITDA remained flat at $51.2 million due to seasonal and weather impacts, but full-year revenue and EBITDA guidance remains strong, bolstered by new leadership and technology integration.

This article highlights bullish sentiments from financial analysts regarding three technology companies: Intuit (INTU), Rubrik, Inc. Class A (RBRK), and Lumexa Imaging Holdings, Inc. (LMRI). Barclays analysts maintained Buy ratings and set price targets for all three companies, noting significant upside potential based on current average price targets and consensus ratings of "Strong Buy." The article details specific analyst ratings, price targets, and key success metrics for each analyst mentioned.